Compare Dyne Therapeutics Inc. Common Stock (DYN) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs FedEx Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while FedEx Corporation trades at $291.98 (market cap $68.77B). The key difference: FedEx Corporation is far larger — about 24× Dyne Therapeutics Inc. Common Stock's market cap, and FedEx Corporation pays a 1.68% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and FedEx Corporation for 87 Days on average.
| DYN | FDX | |
|---|---|---|
Market Cap | $2.86B | $68.77B |
Volume | 3,341,579 | 914,308 |
Sector | Health | Industrials |
52-Week High | $26.78 | $339.35 |
52-Week Low | $14.60 | $189.87 |
Typical Hold Time | 0 Days | 87 Days |
Enterprise Value | $2.18B | $98.41B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FedEx (FDX) trades at $291.28, down 0.33% on the day, with a bearish technical signal. The stock shows solid fundamentals with a P/E of 15.67 and net income margin of 4.68%, though revenue has been flat recently. Recent news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow is projected to improve significantly in 2026.
The outlook is mixed: strong analyst buy consensus (57%) and a $307.55 price target suggest upside, but technical indicators and rising fuel costs pose near-term risks. Long-term growth depends on execution of cost cuts and capitalizing on industry tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
